Last C$1.94 CAD
Change Today 0.00 / 0.00%
Volume 0.0
HBP On Other Exchanges
Symbol
Exchange
Toronto
OTC US
Frankfurt
As of 2:19 PM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

helix biopharma corp (HBP) Snapshot

Open
C$1.77
Previous Close
C$1.94
Day High
C$2.00
Day Low
C$1.70
52 Week High
06/10/14 - C$2.27
52 Week Low
08/7/13 - C$0.90
Market Cap
147.2M
Average Volume 10 Days
18.2K
EPS TTM
--
Shares Outstanding
75.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HELIX BIOPHARMA CORP (HBP)

Related News

No related news articles were found.

helix biopharma corp (HBP) Related Businessweek News

No Related Businessweek News Found

helix biopharma corp (HBP) Details

Helix BioPharma Corp., a biopharmaceutical company, develops drugs for the prevention and treatment of cancer based on its proprietary technologies. The company focuses on the development of L-DOS47 that is in phase I/II clinical trial for the treatment of inoperable, locally advanced, and recurrent or metastatic non-small cell lung cancer; and Topical Interferon Alpha-2b, which has completed phase II study for the treatment of low-grade cervical lesions and ano-genital warts caused by human papilloma virus infections. It also offers DOS47, a patented oncology platform technology that derives a therapeutic pharmacological effect by acting upon a naturally occurring substance in the body. Helix BioPharma Corp. is based in Aurora, Canada.

12.5 Employees
Last Reported Date: 10/29/13

helix biopharma corp (HBP) Top Compensated Officers

Chief Executive Officer, President and Non-In...
Total Annual Compensation: C$325.0K
Chief Financial Officer
Total Annual Compensation: C$260.0K
Chief Scientific Officer
Total Annual Compensation: C$275.0K
Compensation as of Fiscal Year 2013.

helix biopharma corp (HBP) Key Developments

Helix Biopharma Corp. Announces Board Changes

Helix BioPharma Corp. announced the appointment of Mr. Yvon Bastien as the new Chair of the board effective July 17, 2014. Mr. Bastien has served as an independent director of the company since December 2013 and remains the Chair of the board's Governance & Compensation Committee. Mr. Robert Verhagen has served as Interim Chair since December 2013 and remains a Director of the company and President and CEO. Mr. Bastien has served in leadership roles within the life sciences industry for over 30 years, most recently as past President of Sanofi Canada and past President of Jouveniel.

Helix Biopharma Corp. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended April 30, 2014

Helix Biopharma Corp. announced unaudited consolidated earnings results for the third quarter and nine months ended April 30, 2014. For the quarter, the company reported loss from operating activities before finance items of $2,114,000 against $2,214,000 a year ago. Loss and total comprehensive loss from continuing operations was $2,109,000 against $2,155,000 a year ago. Net loss and total comprehensive loss was $2,109,000 against $2,224,000 a year ago. Total basic and diluted loss per common share was $0.03 against $0.03 a year ago. Net cash used in operating activities was $1,553,000 against $1,576,000 a year ago. For the nine months, the company reported loss before finance items of $6,932,000 against $6,321,000 a year ago. Loss and total comprehensive loss from continuing operations was $6,878,000 against $6,281,000 a year ago. Net loss and total comprehensive loss was $6,878,000 against net profit and total comprehensive profit of $368,000 a year ago. Total basic and diluted loss per common share was $0.10 against total basic and diluted income per common share of $0.01 a year ago. Net cash used in operating activities was $6,364,000 against $5,667,000 a year ago.

Helix Biopharma Corp. Submits L-DOS47 Clinical Trial Application with Health Canada

Helix BioPharma Corp. announced the recent submission of a Clinical Trial Application with Health Canada for approval to initiate a Phase I clinical trial with L-DOS47. The study is entitled 'A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Vinorelbine in Patients with Metastatic or Advanced Solid Tumours'. L-DOS47 is Helix's first immunoconjugate-based drug candidate in development based upon the company's novel DOS47 technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction. L-DOS47 is currently being clinically evaluated as a treatment for certain patients with non-small cell lung cancer. The company currently has a European Phase I/II L-DOS47 monotherapy clinical trial ongoing in Poland and has recently received approval from the U.S. Food and Drug administration for a Phase I clinical trial of L-DOS47 in combination with pemetrexed/carboplatin.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HBP:CN C$1.94 CAD 0.00

HBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HBP.
View Industry Companies
 

Industry Analysis

HBP

Industry Average

Valuation HBP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 46.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HELIX BIOPHARMA CORP, please visit www.helixbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.